These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37251393)

  • 1. Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis.
    Wang H; Song C; Zhao X; Deng W; Dong J; Shen W
    Front Immunol; 2023; 14():1170569. PubMed ID: 37251393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
    Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
    Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis.
    Wang Z; Shao C; Wang Y; Duan H; Pan M; Zhao J; Wang J; Ma Z; Li X; Yan X
    Int J Surg; 2022 Aug; 104():106767. PubMed ID: 35840049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
    He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
    Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis.
    Wang M; Dong W; Liu A; Lai T; Zhang B; Sun Q
    Transl Cancer Res; 2024 Jun; 13(6):2735-2750. PubMed ID: 38988921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis.
    Wang H; Li S; Liu T; Chen J; Dang J
    Front Immunol; 2022; 13():998620. PubMed ID: 36177019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
    Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
    JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
    Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
    World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
    Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis.
    Bao Y; Ma Z; Yuan M; Wang Y; Men Y; Hui Z
    Thorac Cancer; 2022 Sep; 13(17):2515-2523. PubMed ID: 35891585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does neoadjuvant therapy contribute to increased risk in anastomotic leakage of esophageal cancer? A network meta-analysis.
    Zhou D; Chen D; Song P; Hu Z; Xu S; Zhu R; Chen Y
    J Evid Based Med; 2024 Sep; 17(3):559-574. PubMed ID: 39161209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.
    Xu H; Li T; Shao G; Wang W; He Z; Xu J; Qian Y; Liu H; Ge H; Wang L; Zhang D; Yang L; Li F; Xu Z
    Front Immunol; 2023; 14():1193614. PubMed ID: 37426646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
    Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
    Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
    Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
    Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of Short-term Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy and Surgery Alone for Locally Advanced Resectable 
Non-small Cell Lung Cancer].
    Li H; Liu Q; Li B; Chen Y; Lin J; Meng Y; Feng H; Zheng Z; Hui Y
    Zhongguo Fei Ai Za Zhi; 2024 Jun; 27(6):421-430. PubMed ID: 39026493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
    J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis.
    Zhao J; Hao S; Li Y; Liu X; Liu Z; Zheng C; Han D
    Immunotargets Ther; 2023; 12():113-133. PubMed ID: 38026088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.